Discovery and mechanism verification of first-in-class hydrophobic tagging-based degraders of HBV core protein

Discovery and mechanism verification of first-in-class hydrophobic tagging-based degraders of HBV core protein

Interfering hepatitis B virus (HBV) capsid assembly holds promise as a therapeutic approach for chronic hepatitis B (CHB). Novel anti-HBV agents are urgently needed to overcome drug resistance challenges, with targeted protein degradation (TPD) emerging as a hopeful strategy. Herein, we report the f...

Full description

Saved in:
Bibliographic Details
Main Authors: Shujing Xu, Ya Wang, Dazhou Shi, Shuo Wang, Lijun Qiao, Ge Yang, Yang Zhou, Xinyong Liu, Shuo Wu, Yuhuan Li, Peng Zhan
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Hepatitis B virus
Core protein
Hydrophobic tagging
Degrader
Mechanism verification
Drug resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383525001108
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interfering hepatitis B virus (HBV) capsid assembly holds promise as a therapeutic approach for chronic hepatitis B (CHB). Novel anti-HBV agents are urgently needed to overcome drug resistance challenges, with targeted protein degradation (TPD) emerging as a hopeful strategy. Herein, we report the first degradation of HBV core protein (HBC), a multifunctional structural protein, using small-molecule degraders developed by hydrophobic tagging (HyT) technology. Structure–activity relationship (SAR) analysis identified compound HyT-S7, featuring an adamantyl group, exhibiting potent inhibitory activity (EC50 = 0.46 μmol/L, HepAD38 cells) and degradation ability (DC50 = 3.02 ± 0.54 μmol/L) in a dose- and time-dependent manner. Mechanistic studies demonstrated that the autophagy–lysosome pathway was a potential driver of HyT-S7-induced HBC degradation. Remarkably, HyT-S7 effectively degraded 11 drug-resistant mutants, including highly resistant strains P25G and T33N, to Phase III drug GLS4. Furthermore, cellular thermal shift assay, surface plasmon resonance assay, and molecular dynamics simulations revealed the precise mode of HyT-S7 binding to HBC with the adamantyl group potentially mimicking protein misfolding to facilitate HBC degradation. This first proof-of-concept study highlights the potential of HyT-mediated TPD in HBC as a promising avenue for discovering novel HBV and other antiviral agents with favorable drug resistance profiles.
ISSN:2211-3835

Similar Items